All lobbying filings

ARENTFOX SCHIFF LLP

Lobbying for ORGANOGENESIS INC. · Biotech company

Filing 2nd Quarter - Report

2nd Quarter (Apr 1 - June 30) 2026 · Massachusetts · House · Senate · $80,000.00 income · posted Jul 18, 2026

Official filing document

Bills named in this filing 3

HR 5768
Skin Substitute Access and Payment Reform Act
S 2561
Skin Substitute Access and Payment Reform Act of 2025
HR 6852
Advanced Wound Care and Regenerative Medicine Access and Reform Act

Lobbying activity 2

Medicare/Medicaid

Medicare reimbursement policy for chronic wound healing products, including Local Coverage Determinations and Discarded Products policy Physician Fee Schedule regulations regarding reimbursement for chronic wound healing products (CY2026 and CY2027) Hospital Outpatient Prospective Payment System regulations regarding reimbursement for chronic wound healing products (CY2026 and CY2027) H.R. 5768 and S. 2561 (Skin Substitute Access and Payment Reform Act of 2025), entire bill H.R.6852 (Advanced Wound Care and Regenerative Medicine Access and Reform Act), entire bill

Health Issues

Food and Drug Administration policy on chronic wound healing products

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.